HomeCompareGRGUF vs ABBV

GRGUF vs ABBV: Dividend Comparison 2026

GRGUF yields 52631.58% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GRGUF wins by $7.986841824948223e+23M in total portfolio value
10 years
GRGUF
GRGUF
● Live price
52631.58%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.986841824948223e+23M
Annual income
$795,710,146,136,258,500,000,000,000,000.00
Full GRGUF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GRGUF vs ABBV

📍 GRGUF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGRGUFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GRGUF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GRGUF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GRGUF
Annual income on $10K today (after 15% tax)
$4,473,684.21/yr
After 10yr DRIP, annual income (after tax)
$676,353,624,215,819,700,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GRGUF beats the other by $676,353,624,215,819,700,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GRGUF + ABBV for your $10,000?

GRGUF: 50%ABBV: 50%
100% ABBV50/50100% GRGUF
Portfolio after 10yr
$3.9934209124741116e+23M
Annual income
$397,855,073,068,129,200,000,000,000,000.00/yr
Blended yield
99.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GRGUF
No analyst data
Altman Z
12.3
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GRGUF buys
0
ABBV buys
0
No recent congressional trades found for GRGUF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGRGUFABBV
Forward yield52631.58%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$7.986841824948223e+23M$102.3K
Annual income after 10y$795,710,146,136,258,500,000,000,000,000.00$24,771.77
Total dividends collected$7.984889844873965e+23M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GRGUF vs ABBV ($10,000, DRIP)

YearGRGUF PortfolioGRGUF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$5,273,858$5,263,157.89$11,550$430.00+$5.26MGRGUF
2$2,599,768,898$2,594,125,870.51$13,472$627.96+$2599.76MGRGUF
3$1,197,907,458,231$1,195,125,705,509.77$15,906$926.08+$1197907.44MGRGUF
4$515,939,295,120,189$514,657,534,139,881.20$19,071$1,382.55+$515939295.10MGRGUF
5$207,713,959,232,287,460$207,161,904,186,508,860.00$23,302$2,095.81+$207713959232.26MGRGUF
6$78,168,139,314,512,790,000$77,945,885,378,134,250,000.00$29,150$3,237.93+$78168139314512.75MGRGUF
7$27,497,709,268,240,953,000,000$27,414,069,359,174,423,000,000.00$37,536$5,121.41+$27497709268240952.00MGRGUF
8$9,042,154,837,977,321,000,000,000$9,012,732,289,060,305,000,000,000.00$50,079$8,338.38+$9042154837977321472.00MGRGUF
9$2,779,473,232,302,745,600,000,000,000$2,769,798,126,626,110,300,000,000,000.00$69,753$14,065.80+$2.7794732323027456e+21MGRGUF
10$798,684,182,494,822,400,000,000,000,000$795,710,146,136,258,500,000,000,000,000.00$102,337$24,771.77+$7.986841824948223e+23MGRGUF

GRGUF vs ABBV: Complete Analysis 2026

GRGUFStock

Grand Gulf Energy Limited engages in the exploration and production of helium in the United States. It holds interest in the Red Helium project located in Paradox Basin, Utah; and the Desiree and D&L fields situated in Assumption Parish, Louisiana, as well as in the DJ Basin located in Weld County. The company was formerly known as Alto Energy International Limited and changed its name to Grand Gulf Energy Limited in June 2007. Grand Gulf Energy Limited was incorporated in 1996 and is headquartered in West Perth, Australia.

Full GRGUF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GRGUF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GRGUF vs SCHDGRGUF vs JEPIGRGUF vs OGRGUF vs KOGRGUF vs MAINGRGUF vs JNJGRGUF vs MRKGRGUF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.